Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Researchers Reveal How Aggressive Breast Cancer May Spread to the Brain (opens in a new tab)

scitechdaily.com · 2026-10-05

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Three of five claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 3 supported
  • 2 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredResearchers at Wake Forest University School of Medicine identified SIRPα as a possible contributor and found that reducing or blocking it slowed tumor growth, decreased cancer in the brain, and delayed brain metastases across several preclinical models.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that SIRPα inhibition reduced TNBC brain metastatic lesion burden in mouse metastasis models and that SIRPα overexpression increased systemic metastasis. However, the supplied abstract profile does not verify several story details as stated, including slowed tumor growth, delayed brain metastases, or the exact breadth of effects across several preclinical models. Those may exist in the full paper, but they are not verifiable from the supplied abstract-depth evidence.

1

Study evidence

In the orthotopic mammary fat pad model using TNBC brain‑tropic cells, cancer‑cell SIRPα overexpression significantly increased systemic metastasis (abstract-reported result).

“TNBC brain-tropic cells were injected into the mouse mammary fat pad for the orthotopic tumor model…”
2

Study evidence

In mouse brain-metastasis models (intracardiac injection), inhibition of SIRPα reduced TNBC brain metastatic lesions.

“…and intracardiac-injected for brain metastasis models.”
Claim 2 of 5Not coveredAnalyzing human breast cancer data and patient tumor samples, the researchers found elevated SIRPα levels in TNBC cells, especially in tumors that had reached the brain, and linked higher levels to poorer patient outcomes.View evidenceHide evidence

Why this verdict

The profile supports elevated SIRPα in malignant TNBC epithelial cells and upregulation in patient breast-to-brain metastatic lesions. It does not, at abstract depth, report a patient-outcome or survival analysis linking higher SIRPα levels to poorer outcomes. The poorer-outcomes portion is therefore not verifiable at this evidence depth.

1

Study evidence

Human single-cell RNA-seq re-analysis showed increased SIRPα expression in malignant TNBC epithelial cells, and patient breast-to-brain metastatic lesions were reported to have upregulated SIRPα.

“Human breast cancer scRNAseq profiles were used to examine SIRPα expression across different cell populations and subtypes.”
Claim 3 of 5SupportedA preclinical study links the protein SIRPα to triple-negative breast cancer’s ability to spread to the brain and evade the brain’s immune defenses.View evidenceHide evidence

Why this verdict

The abstract-level profile supports a preclinical link between cancer-intrinsic SIRPα and TNBC brain metastasis/immune escape: SIRPα is elevated in malignant TNBC and breast-to-brain metastatic lesions, inhibition reduced brain metastatic lesions in mouse models, and fibronectin-associated microglial tolerance is presented as an immune-evasion mechanism. The headline is hedged as a link rather than a patient-ready causal claim, so it does not materially outrun the paper at this depth.

1

Study evidence

Human single-cell RNA-seq re-analysis showed increased SIRPα expression in malignant TNBC epithelial cells, and patient breast-to-brain metastatic lesions were reported to have upregulated SIRPα.

“Human breast cancer scRNAseq profiles were used to examine SIRPα expression across different cell populations and subtypes.”
2

Study evidence

In mouse brain-metastasis models (intracardiac injection), inhibition of SIRPα reduced TNBC brain metastatic lesions.

“…and intracardiac-injected for brain metastasis models.”
Claim 4 of 5SupportedThe study suggests SIRPα increases fibronectin production, weakens microglia responses, and promotes mitochondrial fission, changes that may make cancer cells more mobile and help them survive in the brain environment.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the core mechanistic framing: SIRPα perturbation affects mitochondrial dynamics/fission, the paper reports an SHP2/Erk/Drp1-associated fission pathway, and SIRPα-regulated fibronectin is linked to microglial tolerance through impaired inflammatory signaling and metabolic reprogramming. The story’s wording is hedged, though it compresses details such as the specific signaling axis and the abstract does not provide quantitative support.

1

Study evidence

Bulk RNA-Seq following SIRPα perturbation in TNBC cells showed changes in expression of genes involved in mitochondrial dynamics, with pathway analyses emphasizing mitochondrial fission programs as downstream of SIRPα.

“Bulk RNA sequencing was used to determine SIRPα-regulated pathway.”
2

Study evidence

Stable overexpression of SIRPα in TNBC cell lines is reported to increase mitochondrial fission and to activate signaling through SHP2, ERK, and DRP1.

“Stably SIRPα overexpressed and knockout TNBC cell lines were established to determine SIRPα intracellular regulation.”
Claim 5 of 5SupportedThe article says the results remain preclinical and additional studies are needed before the approach can be evaluated in patients.View evidenceHide evidence

Why this verdict

The supplied profile describes basic/preclinical evidence from in vitro TNBC cell models, animal metastasis models, ex vivo animal tumor profiling, and unspecified microglial functional assays, with no patient intervention data. The story’s caveat that results remain preclinical and need further study before patient evaluation is consistent with the paper profile.

1

Study evidence

Bulk RNA-Seq following SIRPα perturbation in TNBC cells showed changes in expression of genes involved in mitochondrial dynamics, with pathway analyses emphasizing mitochondrial fission programs as downstream of SIRPα.

“Bulk RNA sequencing was used to determine SIRPα-regulated pathway.”
2

Study evidence

Stable overexpression of SIRPα in TNBC cell lines is reported to increase mitochondrial fission and to activate signaling through SHP2, ERK, and DRP1.

“Stably SIRPα overexpressed and knockout TNBC cell lines were established to determine SIRPα intracellular regulation.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The abstract-profile human evidence is expression-focused and observational/computational; it does not establish causality and, at this depth, does not report patient survival or clinical outcome associations.

    The story mentions poorer patient outcomes, but the supplied abstract-level profile does not verify that outcome association. The story also does not clearly caveat that the human expression data alone cannot establish causal metastatic function.

    From in_silico scRNA-seq re-analysis and metastatic lesion expression comparison

5 things the story did carry across
  • SIRPα is elevated in malignant TNBC epithelial cells and in patient breast-to-brain metastatic lesions, based on human scRNA-seq re-analysis and metastatic lesion expression assessment.
  • Cancer-cell SIRPα promotes metastatic potential in vivo, and SIRPα inhibition reduced TNBC brain metastatic lesion burden in mouse metastasis models.
  • SIRPα regulates mitochondrial dynamics/fission, with the paper specifically implicating SHP2/Erk/Drp1-associated signaling.
  • SIRPα-regulated extracellular matrix/fibronectin is linked to brain-metastatic immune microenvironment changes and microglial tolerance/immune escape.
  • The evidence base is preclinical/basic research, including cell-line perturbation, mouse metastasis models, spatial profiling of animal tumor tissues, and microglial functional assays; no patient treatment efficacy is shown.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

7

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalCancer-intrinsic SIRPα drives mitochondrial fission via SHP2/Erk/Drp1-associated signaling and promotes systemic/brain metastatic potential of TNBC in vivo; SIRPα inhibition reduces brain metastatic burden in mouse models.in vivo intracardiac brain metastasis modelExpand

In plain English

In mouse metastasis models (intracardiac injection), cancer-cell–intrinsic SIRPα modulates metastatic behavior of TNBC: pharmacologic/genetic inhibition of SIRPα reduced brain metastatic lesion burden, while cancer-cell SIRPα overexpression increases metastatic potential in vivo. The study links SIRPα activity to mitochondrial fission (SHP2/Erk/Drp1) and to changes in the tumor immune microenvironment (fibronectin-associated microglial tolerance) that may facilitate brain colonization.

Key findings

  • In mouse brain-metastasis models (intracardiac injection), inhibition of SIRPα reduced TNBC brain metastatic lesions.
  • Cancer-cell SIRPα overexpression in vivo increased TNBC metastatic potential/systemic metastasis.
“…and intracardiac-injected for brain metastasis models.”
What this piece can’t prove
  • The abstract does not clearly distinguish which metastatic outcomes derive specifically from the intracardiac brain metastasis model versus other in vivo metastasis assays.

2 further details could not be confirmed from the summary.

2in silicoCancer-intrinsic SIRPα is elevated in malignant TNBC cells and in patient breast-to-brain metastatic lesions (including brain-tropic TNBC models), motivating a cancer-cell–intrinsic role in brain metastasis.in silico scRNA-seq re-analysis and metastatic lesion expression comparisonExpand

In plain English

Re-analysis of existing human breast cancer single-cell RNA-seq profiles indicated that SIRPα expression is elevated in malignant TNBC epithelial cells. Separate assessment of patient breast-to-brain metastatic lesions reported upregulation of SIRPα in those metastatic samples.

Key findings

  • Human single-cell RNA-seq re-analysis showed increased SIRPα expression in malignant TNBC epithelial cells, and patient breast-to-brain metastatic lesions were reported to have upregulated SIRPα.
“Human breast cancer scRNAseq profiles were used to examine SIRPα expression across different cell populations and subtypes.”
What this piece can’t prove
  • Unclear whether the metastatic lesion expression comparison controlled for potential confounders (e.g., tissue composition, prior treatment, patient-matching).
  • Findings are based on re-analysis/observational expression data and therefore cannot by themselves demonstrate functional or causal roles.

1 further detail could not be confirmed from the summary.

3in vitroCancer-intrinsic SIRPα drives mitochondrial fission via SHP2/Erk/Drp1-associated signaling and promotes systemic/brain metastatic potential of TNBC in vivo; SIRPα inhibition reduces brain metastatic burden in mouse models.bulk RNA-seq; differential expression; pathway enrichmentExpand

In plain English

Bulk RNA sequencing of TNBC cells with experimental perturbation of SIRPα (targeting/overexpression/knockout) identified differential expression and pathway enrichment implicating mitochondrial dynamics, with emphasis on mitochondrial fission gene programs as SIRPα-regulated.

Key findings

  • Bulk RNA-Seq following SIRPα perturbation in TNBC cells showed changes in expression of genes involved in mitochondrial dynamics, with pathway analyses emphasizing mitochondrial fission programs as downstream of SIRPα.
“Bulk RNA sequencing was used to determine SIRPα-regulated pathway.”
What this piece can’t prove
  • Pathway-level inference from bulk RNA-seq is associative; functional or mechanistic causation requires complementary experiments.
  • Findings from in vitro TNBC cell models may not fully generalize to in vivo or patient tumor contexts without supporting data.

1 further detail could not be confirmed from the summary.

4in vitroCancer-intrinsic SIRPα drives mitochondrial fission via SHP2/Erk/Drp1-associated signaling and promotes systemic/brain metastatic potential of TNBC in vivo; SIRPα inhibition reduces brain metastatic burden in mouse models.in vitro genetic perturbation and signaling/dynamics assaysExpand

In plain English

In TNBC cell lines, the authors generated stable SIRPα overexpression and knockout models and report that SIRPα modulates mitochondrial dynamics: SIRPα upregulation is associated with increased mitochondrial fission and activation of a SHP2→ERK→DRP1 signaling axis, whereas loss of SIRPα has the opposite effect. These in vitro manipulations are presented as mechanistic evidence linking cancer-intrinsic SIRPα to mitochondrial fission, which the authors state contributes to metastatic behavior.

Key findings

  • Stable overexpression of SIRPα in TNBC cell lines is reported to increase mitochondrial fission and to activate signaling through SHP2, ERK, and DRP1.
  • SIRPα knockout in TNBC cell lines is reported to reduce the mitochondrial fission phenotype and associated SHP2/ERK/DRP1 signaling relative to SIRPα-overexpressing or parental cells.
“Stably SIRPα overexpressed and knockout TNBC cell lines were established to determine SIRPα intracellular regulation.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

5in vivo animalCancer-intrinsic SIRPα drives mitochondrial fission via SHP2/Erk/Drp1-associated signaling and promotes systemic/brain metastatic potential of TNBC in vivo; SIRPα inhibition reduces brain metastatic burden in mouse models.In vivo orthotopic mammary fat pad tumor implantationExpand

In plain English

Using an orthotopic mouse mammary fat pad model with TNBC brain‑tropic cells, cancer‑cell SIRPα overexpression increased systemic metastasis in vivo. Methods reported in the abstract include orthotopic implantation of genetically modified (SIRPα-overexpressing) TNBC cells and assessment of systemic metastatic spread; numerical effect sizes, sample sizes, and statistical details are not provided in the abstract.

Key findings

  • In the orthotopic mammary fat pad model using TNBC brain‑tropic cells, cancer‑cell SIRPα overexpression significantly increased systemic metastasis (abstract-reported result).
“TNBC brain-tropic cells were injected into the mouse mammary fat pad for the orthotopic tumor model…”
What this piece can’t prove
  • Summary is based solely on abstract text; full methods, experimental details, and quantitative results are not available here.
  • Use of brain‑tropic TNBC cells in the orthotopic model may influence metastatic behavior relative to parental lines; abstract does not present comparative orthotopic data for parental vs brain‑tropic cells.

1 further detail could not be confirmed from the summary.

6ex vivo animalSIRPα-regulated extracellular matrix (notably fibronectin) reshapes the brain metastatic immune microenvironment by inducing microglial tolerance through impaired inflammatory signaling and metabolic reprogramming, enabling immune escape.Digital spatial profiling / spatial proteomics on tissue sections (orthotopic and brain metastasis)Expand

In plain English

Digital spatial proteomic profiling of orthotopic and brain metastatic tumor tissues identified SIRPα-associated changes in the tumor immune microenvironment linked to the extracellular matrix protein fibronectin; the report states fibronectin induces microglial tolerance by impairing inflammatory signaling and metabolic reprogramming, enabling cancer immune escape in brain metastases.

Key findings

  • Spatial proteomics of orthotopic and brain metastasis tissues linked SIRPα regulation to changes in the tumor immune microenvironment associated with the ECM protein fibronectin; fibronectin was reported to induce microglial tolerance by impairing inflammatory signaling and metabolic reprogramming, enabling immune escape.
“Digital spatial profiling was utilized to investigate the orthotopic and brain metastasis tumor immune microenvironment.”
What this piece can’t prove
  • It is not specified whether the spatial proteomic observations represent causal mechanisms versus correlative associations in the tumor microenvironment.

2 further details could not be confirmed from the summary.

7otherSIRPα-regulated extracellular matrix (notably fibronectin) reshapes the brain metastatic immune microenvironment by inducing microglial tolerance through impaired inflammatory signaling and metabolic reprogramming, enabling immune escape.Expand

In plain English

The paper reports that SIRPα-regulated extracellular matrix protein fibronectin is associated with reshaping the brain-metastatic tumor immune microenvironment and functionally induces microglial tolerance by impairing inflammatory signaling and altering microglial metabolic programming, enabling cancer immune escape.

Key findings

  • Fibronectin induces microglial tolerance by impairing inflammatory signaling and metabolic reprogramming, enabling cancer to escape microglial immunosurveillance.
“Fibronectin induces microglial tolerance by impairing inflammatory signaling and metabolic reprogramming, allowing cancer to escape microglial immunosurveillance.”
What this piece can’t prove

4 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 35 candidate papers

Candidate

Author response for "Standalone Photo–Rechargeable Capacitor Integrating DSSCs with a Bi//NiCo2S4 Asymmetric Supercapacitor for High–Efficiency Indoor and Outdoor Energy Storage"

2026 · Crossref

Source (opens in a new tab)

And 29 more candidates considered.